Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

• Published in: Blood research Vol. 48; no. 2; pp. 115 - 120
• Main Authors: Yi, Hyeon Gyu, Kim, Jin Seok, Suh, Cheolwon, Kim, Won Seog, Kwak, Jae-Yong, Lee, Jong-Seok, Kim, Yang Soo, Joo, Young Don, Min, Yoo Hong, Lee, Hong Ghi, Yoon, Sung-Soo, Won, Jong-Ho, Park, Seonyang, Kim, Hugh Chul, Kim, Chul Soo
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 01.06.2013; 대한혈액학회
• Subjects: Original; 병리학; CHOP regimen; Rituximab; Epidemiology; Survival; Diffuse large B-cell lymphoma
• ISSN: 2287-979X; 2288-0011; 2288-0011
• DOI: 10.5045/br.2013.48.2.115

This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes. In 2007-2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990. Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration. The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.